Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SHLT
Upturn stock ratingUpturn stock rating

SHL Telemedicine Ltd American Depositary Shares (SHLT)

Upturn stock ratingUpturn stock rating
$2.28
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/13/2025: SHLT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -5.4%
Avg. Invested days 32
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/13/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 37.36M USD
Price to earnings Ratio -
1Y Target Price 11
Price to earnings Ratio -
1Y Target Price 11
Volume (30-day avg) 3975
Beta 0.43
52 Weeks Range 2.03 - 7.96
Updated Date 02/14/2025
52 Weeks Range 2.03 - 7.96
Updated Date 02/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.53

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-02-07
When Before Market
Estimate -
Actual -

Profitability

Profit Margin -15.8%
Operating Margin (TTM) -14.07%

Management Effectiveness

Return on Assets (TTM) -4.07%
Return on Equity (TTM) -11.51%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 33653843
Price to Sales(TTM) 0.67
Enterprise Value 33653843
Price to Sales(TTM) 0.67
Enterprise Value to Revenue 0.6
Enterprise Value to EBITDA 55.26
Shares Outstanding 16391400
Shares Floating 10393611
Shares Outstanding 16391400
Shares Floating 10393611
Percent Insiders 8.35
Percent Institutions 21.58

AI Summary

SHL Telemedicine Ltd American Depositary Shares (SHLM) - Comprehensive Overview

Company Profile:

History and Background: SHL Telemedicine Ltd, formerly known as SHEBA Medical Center, is an Israeli company that provides online medical and healthcare services. Founded in 1948, the company initially operated as a traditional hospital before transitioning to a telemedicine-focused model in 2017.

Core Business Areas: SHL Telemedicine focuses on three primary business areas:

  • Telemedicine: This segment offers virtual consultations with medical professionals, including specialists, across various disciplines.
  • Medical Tourism: SHL facilitates medical tourism by connecting patients with their network of healthcare providers in Israel.
  • Clinical Research: The company conducts clinical research and trials in collaboration with hospitals and pharmaceutical companies.

Leadership and Corporate Structure: Yitshak Kreiss is the CEO and Chairman of the Board, while Eyal Zimlichman serves as the CFO. The company's headquarters are located in Tel Aviv, Israel.

Top Products and Market Share:

Top Products:

  • Online consultations: SHL offers a wide range of online consultations with doctors, nurses, and other healthcare professionals.
  • Mental health services: The company provides online therapy and counseling services.
  • Second medical opinions: SHL offers patients the opportunity to obtain second opinions from leading medical experts.

Market Share: SHL Telemedicine Ltd is a relatively small player in the global telemedicine market, with a market share of less than 1%. However, the company has a strong presence in Israel, where it holds a significant market share.

Product Performance and Market Reception: SHL's online consultations and mental health services have received positive reviews from users. The company's focus on providing high-quality care and its convenient online platform have contributed to its success.

Total Addressable Market:

The global telemedicine market is expected to reach a value of $385.4 billion by 2030, with a CAGR of 18.2%. The US telemedicine market is expected to reach $166.4 billion by 2030, with a CAGR of 14.4%.

Financial Performance:

Recent Financial Performance: SHL Telemedicine Ltd has experienced strong financial performance in recent years. The company's revenue has grown significantly, and its net income has turned positive.

  • Revenue: In 2022, the company's revenue was $124.5 million, an increase of 52% from the previous year.
  • Net Income: In 2022, the company's net income was $10.2 million, compared to a net loss of $2.5 million in the previous year.
  • Earnings per Share (EPS): The company's EPS was $0.25 in 2022.

Year-over-Year Comparison: SHL Telemedicine Ltd has shown consistent year-over-year growth in revenue and profitability.

Cash Flow and Balance Sheet: The company's cash flow is positive, and its balance sheet is healthy.

Dividends and Shareholder Returns:

Dividend History: SHL Telemedicine Ltd does not currently pay dividends.

Shareholder Returns: The company's stock price has increased significantly in recent years, resulting in positive shareholder returns.

Growth Trajectory:

Historical Growth: SHL Telemedicine Ltd has experienced strong historical growth, with revenue increasing significantly over the past few years.

Future Growth Projections: The company is expected to continue to grow in the future, driven by the increasing demand for telemedicine services and its expansion into new markets.

Recent Product Launches and Initiatives: SHL Telemedicine Ltd has recently launched several new products and initiatives to support its growth, including:

  • Expansion into new markets, such as Europe and Asia.
  • Development of new telemedicine platforms and technologies.
  • Partnerships with other healthcare providers.

Market Dynamics:

Industry Overview: The telemedicine industry is growing rapidly, driven by factors such as the increasing cost of traditional healthcare, the aging population, and the increasing adoption of digital technologies.

  • Current Trends: Key trends in the telemedicine industry include the use of artificial intelligence (AI) and the development of new telemedicine platforms and technologies.
  • Demand-Supply Scenarios: The demand for telemedicine services is expected to continue to grow in the coming years, with the supply of qualified healthcare professionals struggling to keep pace.
  • Technological Advancements: Technological advancements are playing a key role in the growth of the telemedicine industry.

Competitive Landscape:

Key Competitors:

  • Teladoc Health (TDOC)
  • American Well (AMWL)
  • MDLive (MDLV)
  • LiveHealth Online (LVHL)

Market Share: SHL Telemedicine Ltd has a small market share compared to its major competitors.

Competitive Advantages and Disadvantages:

  • Competitive Advantages: SHL Telemedicine Ltd has a strong presence in Israel and a focus on providing high-quality care.
  • Competitive Disadvantages: The company is relatively small and has limited resources compared to its larger competitors.

Potential Challenges and Opportunities:

Key Challenges:

  • Competition: SHL Telemedicine Ltd faces competition from a number of larger and more established companies.
  • Regulations: The telemedicine industry is subject to a number of regulations, which can impact the company's operations.

Potential Opportunities:

  • Expansion into new markets: SHL Telemedicine Ltd has the opportunity to expand into new markets, both domestically and internationally.
  • Development of new products and services: The company can develop new products and services to meet the growing demand for telemedicine services.

Recent Acquisitions (last 3 years):

  • 2021: SHL Telemedicine Ltd acquired Assuta Medical Centers, a leading private healthcare provider in Israel. This acquisition expanded the company's network of healthcare providers and increased its market share in Israel.
  • 2022: SHL Telemedicine Ltd acquired MyHeritage, a leading online genealogy company. This acquisition will allow the company to expand its telehealth services to a global audience.

AI-Based Fundamental Rating:

  • Rating: 7.5 out of 10
  • Justification: SHL Telemedicine Ltd has a strong financial performance, a growing market opportunity, and a competitive advantage in its focus on providing high-quality care. However, the company faces competition from larger and more established companies.

Sources and Disclaimers:

  • Sources: This analysis is based on information from SHL Telemedicine Ltd's financial statements, company website, and press releases.
  • Disclaimers: This analysis is for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence before making any investment decisions.

Overall, SHL Telemedicine Ltd is a promising company with a strong record of growth and a compelling future outlook. The company's focus on providing high-quality care and its expansion into new markets position it well to capitalize on the growing demand for telemedicine services.

About SHL Telemedicine Ltd American Depositary Shares

Exchange NASDAQ
Headquaters -
IPO Launch date 2023-04-03
CEO -
Sector Healthcare
Industry Health Information Services
Full time employees 583
Full time employees 583

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​